Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cathflo Activase to Enhance Talc Slurry Pleurodesis
NCT04806373Phase 4Completed
- Sponsor
- Memorial Healthcare System
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pleural effusion comparing Talc Slurry Pleurodesis + Cathflo Activase with Talc Slurry Pleurodesis + Placebo (2 arms). Primary endpoint: Radiographically Satisfactory Pleurodesis at 5 days. Started Jun 2021; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
pleural effusion
Beyond the preview
Go deeper on NCT04806373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806373.